Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
Hiroaki TaniokaMichitaka HondaChihiro TanakaYoshitaka MoritaKeiichiro IshibashiTakeshi KatoChu MatsudaMasato KataokaHironaga SatakeYoshinori MunemotoKenji KobayashiMasazumi TakahashiKen NakataJunichi SakamotoKoji ObaHideyuki MishimaPublished in: International journal of clinical oncology (2019)
Biweekly SOX regimen with reintroduction of oxaliplatin could be exploitable as the third- and/or later-line treatments for patients with mCRC.